Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Virol ; 87(6): 3087-96, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23283958

RESUMEN

PARV4 is a small DNA human virus that is strongly associated with hepatitis C virus (HCV) and HIV infections. The immunologic control of acute PARV4 infection has not been previously described. We define the acute onset of PARV4 infection and the characteristics of the acute-phase and memory immune responses to PARV4 in a group of HCV- and HIV-negative, active intravenous drug users. Ninety-eight individuals at risk of blood-borne infections were tested for PARV4 IgG. Gamma interferon enzyme-linked immunosorbent spot assays, intracellular cytokine staining, and a tetrameric HLA-A2-peptide complex were used to define the T cell populations responding to PARV4 peptides in those individuals who acquired infection during the study. Thirty-five individuals were found to be PARV4 seropositive at the end of the study, eight of whose baseline samples were found to be seronegative. Persistent and functional T cell responses were detected in the acute infection phase. These responses had an active, mature, and cytotoxic phenotype and were maintained several years after infection. Thus, PARV4 infection is common in individuals exposed to blood-borne infections, independent of their HCV or HIV status. Since PARV4 elicits strong, broad, and persistent T cell responses, understanding of the processes responsible may prove useful for future vaccine design.


Asunto(s)
Linfocitos T CD8-positivos/inmunología , Infecciones por Parvoviridae/inmunología , Parvovirus/inmunología , Parvovirus/patogenicidad , Citocinas/biosíntesis , Ensayo de Immunospot Ligado a Enzimas , Humanos , Abuso de Sustancias por Vía Intravenosa
2.
J Immunol ; 188(10): 5177-88, 2012 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-22508927

RESUMEN

Vaccines designed to prevent or to treat hepatitis C viral infection must achieve maximum cross-reactivity against widely divergent circulating strains. Rational approaches for sequence selection to maximize immunogenicity and minimize genetic distance across circulating strains may enhance vaccine induction of optimal cytotoxic T cell responses. We assessed T cell recognition of potential hepatitis C virus (HCV) vaccine sequences generated using three rational approaches: combining epitopes with predicted tight binding to the MHC, consensus sequence (most common amino acid at each position), and representative ancestral sequence that had been derived using bayesian phylogenetic tools. No correlation was seen between peptide-MHC binding affinity and frequency of recognition, as measured by an IFN-γ T cell response in HLA-matched HCV-infected individuals. Peptides encoding representative, consensus, and natural variant sequences were then tested for the capacity to expand CD8 T cell populations and to elicit cross-reactive CD8 T cell responses. CD8(+) T cells expanded with representative sequence HCV generally more broadly and robustly recognized highly diverse circulating HCV strains than did T cells expanded with either consensus sequence or naturally occurring sequence variants. These data support the use of representative sequence in HCV vaccine design.


Asunto(s)
Hepacivirus/inmunología , Hepatitis C/inmunología , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/metabolismo , Línea Celular , Células Cultivadas , Estudios de Cohortes , Secuencia de Consenso/inmunología , Reacciones Cruzadas/inmunología , Antígenos HLA/inmunología , Hepatitis C/metabolismo , Hepatitis C/virología , Humanos , Fragmentos de Péptidos/síntesis química , Estudios Prospectivos , Vacunas contra Hepatitis Viral/síntesis química , Vacunas contra Hepatitis Viral/inmunología , Vacunas contra Hepatitis Viral/metabolismo
3.
J Infect Dis ; 204(11): 1730-40, 2011 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-21984735

RESUMEN

BACKGROUND: Proinflammatory cytokines play a critical role in antiviral immune responses. Large-scale genome studies have found correlations between single-nucleotide polymorphisms (SNPs) in the interleukin (IL) 18 promoter and spontaneous control of hepatitis C virus (HCV), suggesting a role in clearance. METHODS: Plasma IL-18, IL-1ß, IL-6, IL-8, IL-12, interferon-γ, tumor necrosis factor-α, alanine aminotransferase (ALT), and HCV RNA levels were assessed longitudinally in subjects with known dates of HCV acquisition and analyzed according to IL-18 SNPs and outcome, either spontaneous clearance (SC) (n = 13) or persistent infection (PI) (n = 25). RESULTS: No significant change in plasma proinflammatory cytokine expression was observed with the exception of IL-18, which increased in every subject with initial detection of HCV RNA. In every SC subject, IL-18 returned to the preinfection baseline concomitant with HCV control. In PI subjects, IL-18 declined following the acute phase of infection but remained above the preinfection baseline throughout chronic infection and did not correlate with HCV RNA or ALT levels. CONCLUSIONS: Plasma IL-18 was an early and the most reliably detected host response to HCV infection measured in blood. Reduced IL-18 production with transition to chronic infection without correlation with HCV RNA or ALT levels suggests modulation of the innate response with persistent infection.


Asunto(s)
Hepatitis C/inmunología , Interleucina-18/sangre , Enfermedad Aguda , Alanina Transaminasa/sangre , Biomarcadores/sangre , Genotipo , Hepatitis C/genética , Humanos , Interleucina-18/genética , Estudios Longitudinales , Polimorfismo de Nucleótido Simple , ARN Viral/sangre , Estadísticas no Paramétricas
4.
J Immunol ; 181(12): 8215-25, 2008 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-19050238

RESUMEN

Hepatitis C virus (HCV) is an important human pathogen that represents a model for chronic infection given that the majority of infected individuals fail to clear the infection despite generation of virus-specific T cell responses during the period of acute infection. Although viral sequence evolution at targeted MHC class I-restricted epitopes represents one mechanism for immune escape in HCV, many targeted epitopes remain intact under circumstances of viral persistence. To explore alternative mechanisms of HCV immune evasion, we analyzed patterns of expression of a major inhibitory receptor on T cells, programmed death-1 (PD-1), from the time of initial infection and correlated these with HCV RNA levels, outcome of infection, and sequence escape within the targeted epitope. We show that the level of PD-1 expression in early HCV infection is significantly higher on HCV-specific T cells from subjects who progress to chronic HCV infection than from those who clear infection. This correlation is independent of HCV RNA levels, compatible with the notion that high PD-1 expression on HCV-specific CD8 T cells during acute infection inhibits viral clearance. Viral escape during persistent infection is associated with reduction in PD-1 levels on the surface of HCV-specific T cells, supporting the necessity of ongoing antigenic stimulation of T cells for maintenance of PD-1 expression. These results support the idea that PD-1 expression on T cells specific for nonescaped epitopes contributes to viral persistence and suggest that PD-1 blockade may alter the outcome of HCV infection.


Asunto(s)
Antígenos CD/metabolismo , Proteínas Reguladoras de la Apoptosis/metabolismo , Epítopos de Linfocito T/inmunología , Hepacivirus/inmunología , Hepatitis C Crónica/inmunología , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/virología , Latencia del Virus/inmunología , Enfermedad Aguda , Adulto , Antígenos CD/biosíntesis , Antígenos CD/genética , Antígenos Virales/inmunología , Proteínas Reguladoras de la Apoptosis/biosíntesis , Proteínas Reguladoras de la Apoptosis/genética , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/metabolismo , Linfocitos T CD8-positivos/virología , Epítopos de Linfocito T/genética , Femenino , Hepacivirus/genética , Hepatitis C Crónica/virología , Humanos , Mutación , Receptor de Muerte Celular Programada 1 , Estudios Prospectivos , ARN Viral/genética , ARN Viral/metabolismo , Subgrupos de Linfocitos T/metabolismo , Carga Viral , Latencia del Virus/genética
5.
Clin Cancer Res ; 18(3): 858-68, 2012 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-22147941

RESUMEN

PURPOSE: Listeria monocytogenes (Lm)-based vaccines stimulate both innate and adaptive immunity. ANZ-100 is a live-attenuated Lm strain (Lm ΔactA/ΔinlB). Uptake by phagocytes in the liver results in local inflammatory responses and activation and recruitment of natural killer (NK) and T cells, in association with increased survival of mice bearing hepatic metastases. The Lm ΔactA/ΔinlB strain, engineered to express human mesothelin (CRS-207), a tumor-associated antigen expressed by a variety of tumors, induces mesothelin-specific T-cell responses against mesothelin-expressing murine tumors. These two phase I studies test ANZ-100 and CRS-207 in subjects with liver metastases and mesothelin-expressing cancers, respectively. EXPERIMENTAL DESIGN: A single intravenous injection of ANZ-100 was evaluated in a dose escalation study in subjects with liver metastases. Nine subjects received 1 × 10(6), 3 × 10(7), or 3 × 10(8) colony-forming units (cfu). CRS-207 was evaluated in a dose-escalation study in subjects with mesothelioma, lung, pancreatic, or ovarian cancers. Seventeen subjects received up to 4 doses of 1 × 10(8), 3 × 10(8), 1 × 10(9), or 1 × 10(10) cfu. RESULTS: A single infusion of ANZ-100 was well tolerated to the maximum planned dose. Adverse events included transient laboratory abnormalities and symptoms associated with cytokine release. Multiple infusions of CRS-207 were well tolerated up to 1 × 10(9) cfu, the determined maximum tolerated dose. Immune activation was observed for both ANZ-100 and CRS-207 as measured by serum cytokine/chemokine levels and NK cell activation. In the CRS-207 study, listeriolysin O and mesothelin-specific T-cell responses were detected and 37% of subjects lived ≥15 months. CONCLUSIONS: ANZ-100 and CRS-207 administration was safe and resulted in immune activation.


Asunto(s)
Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/inmunología , Vacunas contra el Cáncer/administración & dosificación , Vacunas contra el Cáncer/inmunología , Proteínas Ligadas a GPI/inmunología , Listeria monocytogenes/inmunología , Neoplasias Hepáticas/terapia , Adulto , Anciano , Vacunas Bacterianas/efectos adversos , Vacunas contra el Cáncer/efectos adversos , Carcinoma/secundario , Carcinoma/terapia , Citocinas/sangre , Femenino , Citometría de Flujo , Humanos , Inmunohistoquímica , Neoplasias Hepáticas/inmunología , Neoplasias Hepáticas/secundario , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/terapia , Activación de Linfocitos/inmunología , Recuento de Linfocitos , Masculino , Dosis Máxima Tolerada , Mesotelina , Mesotelioma/patología , Mesotelioma/terapia , Persona de Mediana Edad , Neoplasias Ováricas/patología , Neoplasias Ováricas/terapia , Neoplasias Pancreáticas/patología , Neoplasias Pancreáticas/terapia , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/efectos adversos , Vacunas Atenuadas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA